89 related articles for article (PubMed ID: 25699495)
1. Immunogenicity to the bivalent HPV-16/18 vaccine among adolescent African students exposed to helminths and malaria.
Nakalembe M; Banura C; Namujju PB; Mirembe FM
J Infect Dev Ctries; 2015 Feb; 9(2):197-205. PubMed ID: 25699495
[TBL] [Abstract][Full Text] [Related]
2. Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania.
Brown J; Baisley K; Kavishe B; Changalucha J; Andreasen A; Mayaud P; Gumodoka B; Kapiga S; Hayes R; Watson-Jones D
Vaccine; 2014 Jan; 32(5):611-7. PubMed ID: 24291193
[TBL] [Abstract][Full Text] [Related]
3. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
6. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women.
Petäjä T; Pedersen C; Poder A; Strauss G; Catteau G; Thomas F; Lehtinen M; Descamps D
Int J Cancer; 2011 Nov; 129(9):2147-57. PubMed ID: 21190190
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
[TBL] [Abstract][Full Text] [Related]
9. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
Petäjä T; Keränen H; Karppa T; Kawa A; Lantela S; Siitari-Mattila M; Levänen H; Tocklin T; Godeaux O; Lehtinen M; Dubin G
J Adolesc Health; 2009 Jan; 44(1):33-40. PubMed ID: 19101456
[TBL] [Abstract][Full Text] [Related]
14. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women.
De Carvalho N; Teixeira J; Roteli-Martins CM; Naud P; De Borba P; Zahaf T; Sanchez N; Schuind A
Vaccine; 2010 Aug; 28(38):6247-55. PubMed ID: 20643092
[TBL] [Abstract][Full Text] [Related]
15. Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.
Szarewski A
Expert Rev Vaccines; 2012 Jun; 11(6):645-57. PubMed ID: 22873123
[TBL] [Abstract][Full Text] [Related]
16. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
[TBL] [Abstract][Full Text] [Related]
17. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine.
Schwarz TF; Kocken M; Petäjä T; Einstein MH; Spaczynski M; Louwers JA; Pedersen C; Levin M; Zahaf T; Poncelet S; Hardt K; Descamps D; Dubin G
Hum Vaccin; 2010 Dec; 6(12):1054-61. PubMed ID: 21157180
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
19. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
[TBL] [Abstract][Full Text] [Related]
20. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
